Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (January 2026)

45 slides from Day One Biopharmaceuticals's investor presentation, Jan 12, 2026

  1. Slide 1: Targeted therapies for people of all ages

    Slide 1: Targeted therapies for people of all ages

    Targeted therapies for people of all ages January 2026 Day One Biopharmaceuticals Exhibit 99.3

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life-threatening diseases

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner Commercial-stage biopharmaceutical company Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible Focused on advancing first- or best-in-class medicines for childhood and adult diseases Wh

  5. Slide 5: Positioned for accelerating growth in 2026

    Slide 5: Positioned for accelerating growth in 2026

    Positioned for accelerating growth in 2026 1 As used herein the term, “Cash” means our cash, cash equivalents and short-term investments (unaudited) as of December 31, 2025. Cash, cash equivalents and short-term investments as of December 31, 2025 were $441.1 million (unaudited). Standard of care in

  6. Slide 6: Product candidates and anticipated milestones

    Slide 6: Product candidates and anticipated milestones

    Product Candidate Therapeutic Area Phase 1 Dose Escalation Phase 1 Dose Expansion Phase 2 Phase 3/ Registrational Approved Recent & Anticipated Milestones Tovorafenib Type II RAF Inhibitor OJEMDA brand name in U.S.1 Ex-U.S. Rights: 3 BRAF-altered relapsed pLGG 3-year follow-up data publication submi

  7. Slide 7: Well positioned for sustained growth and value generation

    Slide 7: Well positioned for sustained growth and value generation

    Well positioned for sustained growth and value generation $1B+ revenue opportunity in 3 high unmet need indications OJEMDA in R/R pLGG OJEMDA expansion in 1L pLGG Emi-Le in ACC Durable, growing revenue foundation Expands earlier into treatment paradigm Additive topline revenue Third, high-value prog

  8. Slide 8: Relapsed or refractory BRAF-altered pLGG OJEMDA

    Slide 8: Relapsed or refractory BRAF-altered pLGG OJEMDA

    Relapsed or refractory BRAF-altered pLGG OJEMDA Nora Living with pLGG

  9. Slide 9: A serious and life-threatening disease

    Slide 9: A serious and life-threatening disease

    A serious and life-threatening disease *Incidence of BRAF alterations varies across pLGG subtypes. 1 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-1408. doi:10.1177/0883073809342005. 2 Penman CL et al. Front Oncol. 2015;5:54. 3 Cohen AR., N Engl J Med. 2020;386

  10. Slide 10: Tablet formulation and pediatric-friendly powder for oral suspension

    Slide 10: Tablet formulation and pediatric-friendly powder for oral suspension

    Available in tablet formulation and pediatric-friendly powder for oral suspension Overview U.S. prescribing information for OJEMDA Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF

  11. Slide 11: OJEMDA is redefining the treatment paradigm in r/r pLGG

    Slide 11: OJEMDA is redefining the treatment paradigm in r/r pLGG

    OJEMDA is redefining the treatment paradigm in relapsed or refractory pLGG Clinical data reinforce OJEMDA’s role in the r/r pLGG treatment paradigm Three-year follow-up data (Society for Neuro-Oncology 2025) reinforce durability of OJEMDA and align with how physicians manage pLGG Growing long-term d

  12. Slide 12: OJEMDA's durable clinical benefit supports adoption as 2L SOC

    Slide 12: OJEMDA's durable clinical benefit supports adoption as 2L SOC

    OJEMDA’s durable clinical benefit supports its adoption as 2L SOC 1 FIREFLY-1 clinical trial data; long-term follow-up data presented at Society for Neuro-Oncology (SNO) 2025, 2 Day One Biopharmaceuticals clinical and commercial experience. 3 39 patients entered a treatment-free observation period,

  13. Slide 13: pLGG epidemiology and addressable opportunity

    Slide 13: pLGG epidemiology and addressable opportunity

    1 US Census. 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. 3 Penman CL et al. Front Oncol. 2015;5:54. 4 Cohen AR., N Engl J Med. 2020;386(20):1922-1931. 5 Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934-2941. 6 Faulkner C, et al. J Neuropathol Exp Neurol. 2015;74(9):867-

  14. Slide 14: ~1,100 unique r/r pLGG treatment decisions annually

    Slide 14: ~1,100 unique r/r pLGG treatment decisions annually

    ~1,100 unique r/r pLGG treatment decisions annually2,3 1 Treatment eligible population is calculated from epidemiology and progression curves; further validated by claims. 2 Based on internal analysis of available U.S. claims data over a rolling 12-month period. Incidence verified by independent thi

  15. Slide 15: Q4 and FY 2025 OJEMDA net product revenues

    Slide 15: Q4 and FY 2025 OJEMDA net product revenues

    $52.8M Q4 2025 OJEMDA Net Product Revenues1 (Unaudited) 1 Estimated Q4 and FY 2025 net revenues are unaudited, preliminary and based on management’s estimate as of the date of this presentation and are subject to completion of the Company’s financial closing procedures. OJEMDA received approval in A

  16. Slide 16: Commercial execution driving strong 2026 OJEMDA outlook

    Slide 16: Commercial execution driving strong 2026 OJEMDA outlook

    Commercial execution driving strong 2026 OJEMDA outlook 1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales. 2 Compounded annual growth represents the comparison of 2025 to the midpoint of 2026 U.S. net product revenue guidance. 3 ~50% growth at the midpoint repr

  17. Slide 17: Positive physician experience continues to build

    Slide 17: Positive physician experience continues to build

    Positive physician experience continues to build across treatment settings 1 Day One Biopharmaceuticals market research, self-reported data fielded September 2025 versus October 2024. Strong Persistency 2L Adoption Increasing 20 months median duration of treatment for EAP patients 75% of EAP patient

  18. Slide 18: Breadth and depth of prescribing by account

    Slide 18: Breadth and depth of prescribing by account

    1 Sequential growth refers to Q3 2025 versus Q2 2025. >60% of prescribing accounts have treated multiple patients with OJEMDA 28% sequential growth in number of accounts with 4 or more patients1 >80% Priority 1 accounts have initiated 4 or more patients Launch Dec 2024 Sept 2025 1 Patient 2-3 Patien

  19. Slide 19: Focused execution driving continued adoption and durability

    Slide 19: Focused execution driving continued adoption and durability

    Focused execution and meaningful progress driving continued adoption and treatment durability through 2025 * On label patients only. OPTIMIZE PERSISTENCE Support physicians and patients to optimize their experience on OJEMDA including effective AE management and reimbursement support Increase depth

  20. Slide 20: OJEMDA IP summary and regulatory designations

    Slide 20: OJEMDA IP summary and regulatory designations

    OJEMDA IP summary and regulatory designations Composition of matter patent of tovorafenib provides protection in the U.S. out to mid-2036 (with patent term extension)1 Patent portfolio covers formulations, manufacturing methods, and uses of tovorafenib, with issued and pending applications potential

  21. Slide 21: FIREFLY-1 Trial

    Slide 21: FIREFLY-1 Trial

    Phase 2 FIREFLY-1 Trial 3-year follow-up data from the FIREFLY-1 trial studying OJEMDA

  22. Slide 22: After OJEMDA cycles, patients could enter an observation period

    Slide 22: After OJEMDA cycles, patients could enter an observation period

    After 26 OJEMDA cycles, patients could enter an observation period* June 6, 2025 data cutoff. *A cycle was counted if a patient had at least 1 dose in a cycle; patients were treated for a planned period of 26 cycles, after which they could continue tovorafenib or opt to enter an observation period.

  23. Slide 23: Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO

    Slide 23: Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO

    Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †ORR for RAPNO included MRs (i.e., ORR=CR+PR+MR). For CR, PR, and MR, confirmation of response by a subsequent scan app

  24. Slide 24: Many patients continued OJEMDA beyond radiographic progression

    Slide 24: Many patients continued OJEMDA beyond radiographic progression

    Many patients continued OJEMDA beyond RAPNO-defined radiographic progression by IRC June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †58 patients had RAPNO-defined PD events reported by the data cutoff. Of patients who had RAPNO-defined

  25. Slide 25: RAPNO PFS and time to next treatment

    Slide 25: RAPNO PFS and time to next treatment

    RAPNO PFS demonstrates efficacy with OJEMDA; time to next treatment more accurately reflects the full clinical benefit June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †Time to next treatment: an exploratory composite endpoint of time f

  26. Slide 26: Tumor rebound was minimal in first months off therapy

    Slide 26: Tumor rebound was minimal in first months off therapy

    Tumor rebound was minimal in the first 6 months off therapy June 6, 2025 data cutoff. Time 0 is the date of the last tumor assessment before the final dose of primary tovorafenib treatment; plot lines extend to the last follow-up assessment (prior to tovorafenib retreatment if applicable). *Tumor re

  27. Slide 27: Early evidence of retreatment activity

    Slide 27: Early evidence of retreatment activity

    Early evidence of retreatment activity observed in the OJEMDA-retreated cohort June 6, 2025 data cutoff. *Based on maximum % change from last scan before retreatment. † As measured by SPPD per RAPNO. Post-treatment observation patients: OJEMDA retreatment (n=8). RAPNO, Response Assessment in Pediatr

  28. Slide 28: 77% of patients treatment free for at least 12 months

    Slide 28: 77% of patients treatment free for at least 12 months

    77% of 39 patients were treatment free for at least 12 months; median treatment-free interval not yet reached June 6, 2025 data cutoff. *Treatment-free interval: an exploratory endpoint of time from the last dose of tovorafenib to the start of subsequent treatment or date of death, whichever was ear

  29. Slide 29: No new safety signals in the 3-year update

    Slide 29: No new safety signals in the 3-year update

    No new safety signals were observed in the 3-year update June 6, 2025 data cutoff. Adverse events were cumulative events from day 1 to the earliest of (last dose + 30 days, start date of subsequent anticancer treatment, data cut, end of study). *TRAEs reported at grade ≥3 in ≥5% of patients. AESI, a

  30. Slide 30: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG

    Slide 30: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG

    Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2 Bradon Living with pLGG since age 11

  31. Slide 31: FIREFLY-2: 1L pLGG largest future growth lever for OJEMDA

    Slide 31: FIREFLY-2: 1L pLGG largest future growth lever for OJEMDA

    FIREFLY-2: 1L pLGG approval represents the largest future growth lever for OJEMDA by doubling the commercial opportunity 1 Based on internal analysis of available U.S. claims data over a rolling 12-month period. Incidence verified by independent third party. Key Value-Creation Milestones FIREFLY-2 e

  32. Slide 32: FIREFLY-2 trial design and endpoints

    Slide 32: FIREFLY-2 trial design and endpoints

    Trial design Endpoints Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib vs SoC chemotherapy Eligibility: Patients aged up to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy Tovorafenib available as tablets and pediatric-friendly liqu

  33. Slide 33: Emi-Le B7-H4-targeted ADC

    Slide 33: Emi-Le B7-H4-targeted ADC

    B7-H4-targeted antibody-drug conjugate (ADC) Emi-Le

  34. Slide 34: Emi-Le: transformational opportunity in Adenoid Cystic Carcinoma

    Slide 34: Emi-Le: transformational opportunity in Adenoid Cystic Carcinoma

    High-impact clinical program parallels OJEMDA’s rapid development and registration Potential first-in-class program targeting a defined, treatment-resistant cancer High unmet medical need with limited therapeutic options No approved treatments today Potential rapid regulatory pathway Emi-Le: Transfo

  35. Slide 35: Emi-Le Program Overview

    Slide 35: Emi-Le Program Overview

    Emi-Le Program Overview 1 Adenoid Cystic Carcinoma Research Foundation, 2 includes both frontline and relapsed ACC. ACC patient population1,2 B7-H4-targeted ADC Mechanism and modality well matched to ACC biology due to highly and uniformly overexpressed B7-H4 Clear evidence of monotherapy activity i

  36. Slide 36: DAY301 PTK7-targeted ADC

    Slide 36: DAY301 PTK7-targeted ADC

    PTK7-targeted antibody-drug conjugate (ADC) DAY301

  37. Slide 37: DAY301: Next generation ADC targeting PTK7

    Slide 37: DAY301: Next generation ADC targeting PTK7

    DAY301: Next generation ADC targeting PTK7 Antibody Payload Linker High-affinity PTK7-targeted IgG1 antibody optimized for tumor penetration while limiting off-target exposure1 High-potency topo-1 payload with enhanced bystander activity2,3 1 Kong et al, Mol Cancer Ther. 2023;22(10):1128-1143, 2 Jot

  38. Slide 38: PTK7: Well-suited as an ADC target

    Slide 38: PTK7: Well-suited as an ADC target

    PTK7: Well-suited as an ADC target 1 Damelin M, et al. Sci Transl Med. 2017;9(372):eaag2611; 2 Devang N, et al. Adv Protein Chem Struct Biol. 2021;124:121–185; 3 Dessaux C, et al. Oncogene. 2024;43(26):1973–1984; 4 https://www.proteinatlas.org/ Accessed May 2025; 5. Lhoumeau A-C, et al. Cell Cycle.

  39. Slide 39: DAY301: Improved tumor regression vs. benchmarks in preclinical models

    Slide 39: DAY301: Improved tumor regression vs. benchmarks in preclinical models

    DAY301: Improved tumor regression activity demonstrated vs. benchmarks in multiple preclinical models Adapted from Kong C, et al. Mol Cancer Ther. 2023;22:1128–1143. PDX 362797 SCLC H-score 210 PDX 362310 TNBC H-score 255 PDX LD1-200615 HNSCC H-score 120 Indicates drug administration DAY301 has been

  40. Slide 40: DAY301: Initial Phase 1a/b clinical trial design

    Slide 40: DAY301: Initial Phase 1a/b clinical trial design

    RD, Recommended Dose; BOIN, Bayesian Optimal Interval. DAY301: Initial Phase1a/b clinical trial design Phase 1a: Monotherapy Dose Escalation Dose Level 1 Key Design Elements BOIN design for efficiency of dose escalation Backfill active dose levels to generate additional safety data Enroll tumor type

  41. Slide 41: ra G = E = Yn

    Slide 41: ra G = E = Yn

    ra G = E = Yn

  42. Slide 42: Third quarter 2025 financial results

    Slide 42: Third quarter 2025 financial results

    Third quarter 2025 financial results All financial information is unaudited. 1 Includes stock-based compensation expense of $3.0 million and $10.8 million for the three and nine months ended 9/30/25, and $3.8 million and $13.2 million for the three and nine months ended 9/30/24. 2 Includes stock-bas

  43. Slide 43: Day One poised for a transformational 2026

    Slide 43: Day One poised for a transformational 2026

    Day One poised for a transformational 2026 Advancing Pipeline Deliver on 2026 net product revenue guidance Complete FIREFLY-2 trial enrollment in 1H 2026, enabling mid-2027 data readout and potential approval in 2028 Expand OJEMDA globally, extending commercial opportunity (Ipsen) Advance Emi-Le: De

  44. Slide 44: Appendix

    Slide 44: Appendix

    Appendix

  45. Slide 45: Tovorafenib mechanism of action

    Slide 45: Tovorafenib mechanism of action

    Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and pediatric-friendly liquid suspension Once weekly dosing Curren

Source: SEC EDGAR · 8-K filed Jan 12, 2026

More decks from Day One Biopharmaceuticals Inc